Search for: "DOW PHARMACEUTICAL SCIENCES, INC."
Results 101 - 120
of 131
Sorted by Relevance
|
Sort by Date
3 May 2014, 8:56 am
Merrell Dow Pharmaceuticals, Inc., 89 F.3d 594, 596-98 (9th Cir. 1996) (affirming exclusion of Dr. [read post]
9 Jul 2009, 4:54 am
Merrrell Dow Pharmaceuticals, Inc., 509 U .S. 579 (1993). [read post]
13 Sep 2019, 6:00 am
Davis,[vii]a decision to which I shall return presently, not because he was concerned about the strain on judicial capacity that would be produced by judicial scrutiny of unintentional discriminatory effect, but because of his narrow view of equal protection more generally.Coan is admirably sensitive to such problems of ambiguous causation, and thus surveys and explores as alternative possible causes for the Court’s doctrines of deference and its occasional (Coan would say frequent) preference… [read post]
23 Jun 2014, 12:57 pm
Ortho Pharmaceutical Corp., 788 F. 2d 741, 744–745 (11th Cir. 1986). [read post]
12 Dec 2021, 2:22 pm
Whitehall Labs., Inc., 874 F. [read post]
6 May 2010, 4:12 pm
Novartis Pharmaceuticals Corp., 564 F. [read post]
19 Mar 2022, 2:09 pm
Consequently, risk assessors may pay heed to any evidence that points to a need for caution, rather than assess the likelihood that a causal relationship in a specific case is more likely than not.[2] In March 2003, Professor Berger organized a symposium,[3] the first Science for Judges program (and the last), where the toxicologist Dr. [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi patent… [read post]
10 Mar 2008, 1:10 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993); General Electric Co. v. [read post]
7 Feb 2008, 10:46 am
In addition, the resolution of any regulatory violation issue needs to be documented with explicit correspondence from the FDA (letters or preserved emails) that any violation has been addressed and cured to the satisfaction of the Agency.None of this is rocket science. [read post]
26 Oct 2009, 6:25 am
Medico (Filewrapper) BPAI finds claim indefinite and not directed to patentable subject under Bilski: Ex parte Hemmat (GRAY On Claims) District Court N D Illinois: KSR obviousness does not require prior art from the same field: Se-Kure Controls, Inc v Diam USA, Inc (Chicago Intellectual Property Law Blog) District Court E D Texas finds plaintiff has standing; agreement transfers ownership and simultaneously a conditional purchase by transferor from transferee: Balsam Coffee… [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
26 Feb 2022, 6:53 pm
” “Dealing with replicability and uncertainty lies at the heart of statistical science. [read post]
30 Aug 2016, 2:33 pm
Wyeth, Inc., Dr. [read post]
24 Nov 2012, 12:38 pm
In addition, Havner requires that a plaintiff show ‘that he or she is similar to [the subjects] in the studies’ and that ‘other plausible causes of the injury or condition that could be negated [are excluded] with reasonable certainty’.40” 347 S.W.3d at 265 (quoting from Merrell Dow Pharmaceuticals, Inc. v. [read post]
23 Jan 2020, 10:37 pm
Judge Seeborg denied the defense motions against all three of plaintiffs’ plausibility witnesses.[10] The MDL judge determined that biological plausibility is neither necessary nor sufficient for inferring causation in science or in the law. [read post]
13 Apr 2020, 4:19 pm
Effective data science serves to efficiently implement the tools the U.S. [read post]
28 Dec 2017, 2:18 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
2 Dec 2015, 12:38 pm
Metabolife Int’l, Inc., 401 F.3d 1233, 1241 (11th Cir. 2005) (reversing admission of expert witness’s testimony when the witness conceded a dose-response, but failed to address the dose of the medication needed to cause the claimed harm). [read post]
19 Jul 2012, 4:07 pm
Dow Jones & Co., No. [read post]
